.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
AstraZeneca
Daiichi Sankyo
Deloitte
Medtronic
Mallinckrodt
Queensland Health
McKesson
Moodys
Merck

Generated: December 12, 2017

DrugPatentWatch Database Preview

Abraxis Bioscience Company Profile

« Back to Dashboard

What is the competitive landscape for ABRAXIS BIOSCIENCE, and when can generic versions of ABRAXIS BIOSCIENCE drugs launch?

ABRAXIS BIOSCIENCE has one approved drug.

There are thirteen US patents protecting ABRAXIS BIOSCIENCE drugs on ABRAXIS BIOSCIENCE drugs in the past three years.

There are two hundred and sixty-six patent family members on ABRAXIS BIOSCIENCE drugs in thirty-one countries and twelve supplementary protection certificates in nine countries.

Summary for Abraxis Bioscience

International Patents:266
US Patents:13
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Abraxis BioscienceABRAXANEpaclitaxelFOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Abraxis BioscienceABRAXANEpaclitaxelFOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Abraxis BioscienceABRAXANEpaclitaxelFOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Abraxis BioscienceABRAXANEpaclitaxelFOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Abraxis BioscienceABRAXANEpaclitaxelFOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Abraxis BioscienceABRAXANEpaclitaxelFOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Abraxis BioscienceABRAXANEpaclitaxelFOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Abraxis BioscienceABRAXANEpaclitaxelFOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Abraxis BioscienceABRAXANEpaclitaxelFOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Abraxis BioscienceABRAXANEpaclitaxelFOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Abraxis Bioscience

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abraxis BioscienceABRAXANEpaclitaxelFOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005► Subscribe► Subscribe
Abraxis BioscienceABRAXANEpaclitaxelFOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005► Subscribe► Subscribe
Abraxis BioscienceABRAXANEpaclitaxelFOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005► Subscribe► Subscribe
Abraxis BioscienceABRAXANEpaclitaxelFOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005► Subscribe► Subscribe
Abraxis BioscienceABRAXANEpaclitaxelFOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005► Subscribe► Subscribe
Abraxis BioscienceABRAXANEpaclitaxelFOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005► Subscribe► Subscribe
Abraxis BioscienceABRAXANEpaclitaxelFOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005► Subscribe► Subscribe
Abraxis BioscienceABRAXANEpaclitaxelFOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ABRAXIS BIOSCIENCE drugs

Drugname Dosage Strength Tradename Submissiondate
paclitaxel protein-bound particlesFor Injection Suspension100 mg/vialABRAXANE12/11/2015

Non-Orange Book Patents for Abraxis Bioscience

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,012,519Compositions and methods of delivery of pharmacological agents► Subscribe
5,665,382 Methods for the preparation of pharmaceutically active agents for in vivo delivery► Subscribe
5,665,383 Methods for the preparation of immunostimulating agents for in vivo delivery► Subscribe
5,650,156 Methods for in vivo delivery of nutriceuticals and compositions useful therefor► Subscribe
6,537,579 Compositions and methods for administration of pharmacologically active compounds► Subscribe
5,639,473 Methods for the preparation of nucleic acids for in vivo delivery► Subscribe
7,780,984Methods and compositions for treating proliferative diseases► Subscribe
5,916,596 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof► Subscribe
5,834,025 Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions► Subscribe
5,362,478 Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Abraxis Bioscience Drugs

Country Document Number Estimated Expiration
New Zealand335133► Subscribe
World Intellectual Property Organization (WIPO)9814175► Subscribe
Japan2014043454► Subscribe
Norway996433► Subscribe
European Patent Office1337249► Subscribe
China1237901► Subscribe
BrazilPI0607809► Subscribe
Australia5035900► Subscribe
China1515246► Subscribe
European Patent Office2359859► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Abraxis Bioscience Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014 00034Denmark► SubscribePRODUCT NAME: PACLITAXEL FORMULERET SOM ALBUMINBUNDNE NANOPARTIKLER; REG. NO/DATE: C(2013)9835 20131220
613Luxembourg► Subscribe91613, EXPIRES: 20220924
/2014Austria► SubscribePRODUCT NAME: PACLITAXEL, DAS ALS ALBUMIN GEBUNDENE NANOPARTIKEL FORMUIERT IST.; REGISTRATION NO/DATE: EU/1/07/428 (MITTEILUNG) (GEAENDERT DURCH C(2013) 9835) 20131230
C0050France► SubscribePRODUCT NAME: PACLITAXEL ALBUMINE; REGISTRATION NO/DATE IN FRANCE: EU/1/07/428/001 DU 20080111; REGISTRATION NO/DATE AT EEC: EU/1/07/428/001 DU 20080111
2014000065Germany► SubscribePRODUCT NAME: PACLITAXEL ALS AN ALBUMIN GEBUNDENE NANOPARTIKEL-FORMULIERUNG; REGISTRATION NO/DATE: K(2013)9835 20131220
2009 00036Denmark► Subscribe
41/2009Austria► SubscribePRODUCT NAME: PACLITAXEL ALBUMIN
0673Netherlands► SubscribePRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
2014022Lithuania► SubscribePRODUCT NAME: PACLITAXELUM; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
1Finland► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
QuintilesIMS
McKinsey
Chubb
Boehringer Ingelheim
Accenture
Mallinckrodt
Chinese Patent Office
Julphar
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot